Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Darken

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
American Journal of Respiratory and Critical Care Medicine|January 14, 2021
Reply to López-Campos <i>et al.</i> and to Rogliani and CalzettaFernando J Martinez, Patrick Darken, Paul Dorinsky
The Lancet. Respiratory Medicine|August 22, 2021
Perplexing mortality data from triple therapy trials in COPD - Author's replyFernando J Martinez, Patrick Darken, Paul Dorinsky, et al.
Respiratory Research|June 29, 2021
Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil countsShigeo Muro, Hisatoshi Sugiura, Patrick Darken, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|October 19, 2007
Ciclesonide and beclomethasone dipropionate coadministration: effect on cortisol in perennial allergic rhinitisPaul Ratner, Patrick Darken, Mark Wingertzahn, et al.
Pharmaceutical Statistics|March 22, 2020
The attributable estimand: A new approach to account for intercurrent eventsPatrick Darken, Jack Nyberg, Shaila Ballal, et al.
Respiratory Research|August 10, 2021
Corrections to: Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil countsShigeo Muro, Hisatoshi Sugiura, Patrick Darken, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|September 22, 2007
Intranasal ciclesonide coadministration with inhaled fluticasone propionate-salmeterol does not suppress cortisol in allergic rhinitis patientsKenneth Kim, Javier Quesada, Nancy Szmaydy-Rikken, et al.
Clinical Trials (London, England)|December 21, 2023
Algorithmic benchmark modulation: A novel method to develop success rates for clinical studiesBart Ja Willigers, Sridevi Nagarajan, Serban Ghiorghui, et al.
Pulmonary Pharmacology & Therapeutics|March 17, 2018
The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adultsPatrick Darken, Paolo DePetrillo, Colin Reisner, et al.
Chest|June 11, 2003
Cardiovascular safety of salmeterol in COPDGary T Ferguson, Christian Funck-Brentano, Tracy Fischer, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
American Journal of Respiratory and Critical Care Medicine|January 14, 2021
Reply to López-Campos <i>et al.</i> and to Rogliani and CalzettaFernando J Martinez, Patrick Darken, Paul Dorinsky
The Lancet. Respiratory Medicine|August 22, 2021
Perplexing mortality data from triple therapy trials in COPD - Author's replyFernando J Martinez, Patrick Darken, Paul Dorinsky, et al.
Respiratory Research|June 29, 2021
Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil countsShigeo Muro, Hisatoshi Sugiura, Patrick Darken, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|October 19, 2007
Ciclesonide and beclomethasone dipropionate coadministration: effect on cortisol in perennial allergic rhinitisPaul Ratner, Patrick Darken, Mark Wingertzahn, et al.
Pharmaceutical Statistics|March 22, 2020
The attributable estimand: A new approach to account for intercurrent eventsPatrick Darken, Jack Nyberg, Shaila Ballal, et al.
Respiratory Research|August 10, 2021
Corrections to: Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil countsShigeo Muro, Hisatoshi Sugiura, Patrick Darken, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|September 22, 2007
Intranasal ciclesonide coadministration with inhaled fluticasone propionate-salmeterol does not suppress cortisol in allergic rhinitis patientsKenneth Kim, Javier Quesada, Nancy Szmaydy-Rikken, et al.
Clinical Trials (London, England)|December 21, 2023
Algorithmic benchmark modulation: A novel method to develop success rates for clinical studiesBart Ja Willigers, Sridevi Nagarajan, Serban Ghiorghui, et al.
Pulmonary Pharmacology & Therapeutics|March 17, 2018
The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adultsPatrick Darken, Paolo DePetrillo, Colin Reisner, et al.
Chest|June 11, 2003
Cardiovascular safety of salmeterol in COPDGary T Ferguson, Christian Funck-Brentano, Tracy Fischer, et al.
Pageof 5